The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 30, No. 11, pp. 1232-1234.
© 1996 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alderman, C.
Right arrow Articles by Ben-Tovim, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alderman, C.
Right arrow Articles by Ben-Tovim, D.

Research Articles

Effects of serotonin reuptake inhibitors on hemostasis

CP Alderman, P Seshadri, and DI Ben-Tovim

OBJECTIVE: To examine the hematologic safety profile of the selective serotonin reuptake inhibitors (SSRIs), with particular emphasis on the effects of these drugs on platelet aggregation. METHODS: Platelet aggregation studies were undertaken at baseline, and repeated 2 and 4 weeks after the initiation of treatment with an SSRI. Other investigations undertaken included analysis of serum electrolyte and liver enzyme concentrations, complete blood count, and coagulation studies. Patients were also assessed for clinical signs of bleeding. Eight patients (7 treated with fluoxetine, 1 with paroxetine) completed the study protocol. RESULTS: Repeated ANOVA revealed no abnormalities in platelet aggregation, hematopoiesis, or coagulation profile. No patient developed clinical signs of abnormal hemostasis during the study period. A statistically significant elevation in the mean serum bilirubin concentration was detected, but this was not of clinical significance. CONCLUSIONS: Although the SSRIs may cause abnormal hemostasis, this effect is probably rare. Another possibility is that abnormal hemostasis is more likely to occur when high doses of SSRIs are administered.


This article has been cited by other articles:


Home page
 Am. J. PsychiatryHome page
V. L. Serebruany, R. F. Suckow, T. B. Cooper, C. M. O'Connor, A. I. Malinin, K. R. R. Krishnan, L. T. van Zyl, V. Lekht, A. H. Glassman, and Sertraline Antidepressant Heart Attack Randomized
Relationship Between Release of Platelet/Endothelial Biomarkers and Plasma Levels of Sertraline and N-Desmethylsertraline in Acute Coronary Syndrome Patients Receiving SSRI Treatment for Depression
Am J Psychiatry, June 1, 2005; 162(6): 1165 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
K. L. L. Movig, M. W. H. E. Janssen, J. de Waal Malefijt, P. J. Kabel, H. G. M. Leufkens, and A. C. G. Egberts
Relationship of Serotonergic Antidepressants and Need for Blood Transfusion in Orthopedic Surgical Patients
Arch Intern Med, October 27, 2003; 163(19): 2354 - 2358.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. O. Dalton, C. Johansen, L. Mellemkjaer, H. T. Sorensen, B. Norgard, and J. H. Olsen
Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding: A Population-Based Cohort Study
Arch Intern Med, January 13, 2003; 163(1): 59 - 64.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1996 by Harvey Whitney Books Company.